Saredutant

Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[1]

Saredutant
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.111.408
Chemical and physical data
FormulaC31H35Cl2N3O2
Molar mass552.54 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References

  1. http://www.sanofi-aventis.com/binaries/Lettre18_FR_Web_acc_tcm29-25341.pdf Letter to the stockholders of Sanofi-Aventis on May 2009


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.